By Mitchell Gonzales, AES Clean Technology
Nowhere in the product development timeline does speed to market matter more to patients’ needs, or to the investors who make these treatments possible, than when life-altering medicines, therapies, and devices reach the end phase of clinical trials.
For example, existing and new cell and gene therapies are verging on “curative” treatments, making speed to patients imperative for human conditions inducing severe and irreparable consequences in the absence of available treatments. Initial cell and gene therapy commercial products (e.g., Luxturna, Zolgensma, Yescarta) have elevated the impact and success of these treatments.
Read more about modular cleanroom systems being increasingly chosen over a conventional construction approach due to their accelerated design and installation schedule advantages, as well as their reduced job-site safety risk during installation.